Stock market data from NASDAQ or another reputable financial data provider

FDA Approves Iterum's Oral Antibiotic ORLYNVAH for Uncomplicated UTIs in Women on October 25, 2024

Oct 25, 2024, 03:58 PM

The U.S. Food and Drug Administration (FDA) has approved Iterum Therapeutics' oral antibiotic, ORLYNVAH, for the treatment of uncomplicated urinary tract infections (UTIs) in adult women. This announcement was made on Friday, October 25, 2024. The approval is significant as it addresses a common health issue among women, providing a new treatment option. The FDA's decision follows a period of heightened trading activity for Iterum Therapeutics, indicated by a notable increase in volume prior to the announcement. The company's market capitalization remains low, suggesting potential for growth following this approval.